Trividia Health

Trividia Health

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Trividia Health is a well-established, privately-held US company operating in the diabetes diagnostics and digital health sectors. Founded in 1985, it has a long history in the glucose monitoring market, primarily through its TRUE brand of blood glucose meters, test strips, and lancing devices. The company's strategy centers on providing reliable, cost-effective self-monitoring solutions directly to consumers through major retail channels, supplemented by patient education initiatives. Its position is that of a mature, commercial-stage player in the competitive diabetes care market.

DiabetesMetabolic Disease

Technology Platform

Electrochemical blood glucose monitoring systems (TRUE brand), with an indicated focus on digital health integration for data management and patient education.

Opportunities

The growing global prevalence of diabetes ensures sustained demand for monitoring tools.
Trividia's focus on affordable, retail-accessible products positions it well in the cost-conscious segment.
Expanding its digital health offerings could create new value through data services and improved patient engagement.

Risk Factors

The core blood glucose monitoring market faces existential disruption from continuous glucose monitoring (CGM) technology.
Intense competition from larger players and severe pricing pressure on test strips threaten margins.
The company is heavily reliant on the U.S.
retail channel and subject to stringent FDA regulation and reimbursement changes.

Competitive Landscape

Trividia competes in the crowded blood glucose monitoring market against giants like Roche (Accu-Chek), Abbott (FreeStyle), LifeScan (OneTouch), and Ascensia (Contour). Its primary competitive positioning is on value, affordability, and retail accessibility. The broader competitive threat comes from CGM leaders like Dexcom and Abbott, who are shifting the standard of care away from fingerstick testing.